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Case report
We present a family with 2 members who received long-term steroid treatment 
for presumed classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase 
deficiency, until molecular testing revealed nonclassic CAH, not necessarily 
requiring treatment. A 17-year-old male presented to our clinic on glucocorticoid 
and mineralocorticoid treatment for classic CAH. He was diagnosed at 4 years of 
age based on mild-moderate elevations of 17-hydroxyprogesterone (17-OHP) 
and adrenocorticotropic hormone (ACTH), but without evidence of precocious 
adrenarche/puberty. Due to his diagnosis, his clinically asymptomatic 3-year-old 
sister was tested and also found to have elevated ACTH and 17-OHP levels and 
was started on glucocorticoids for classic CAH. Family history revealed a healthy 
sibling who had no biochemical evidence of CAH and consanguineous healthy 
parents. We questioned the diagnosis of classic CAH and performed an ACTH1-24 
stimulation test, which showed a level of 17-OHP in the borderline range between 
classic and nonclassic CAH. Molecular testing, using sequencing and multiplex 
ligation-dependent probe amplification analysis of CYP21A2, revealed that both 
affected siblings were compound heterozygotes for a whole-gene deletion and 
a, likely pathogenic (nonclassical), sequence variant, p.R124C. The asymptomatic 
father had the same genotype, while the mother showed one deleted copy and 2 
active copies, making her an asymptomatic carrier. Our report demonstrates the 
importance of molecular testing in atypical cases of CAH, as well as the importance 
of both sequencing and deletion analysis. The results of molecular testing should 
be interpreted in clinical context, and treatment should be prescribed according to 
guidelines when available.
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Introduction
Congenital adrenal hyperplasia (CAH) is a group of autosomal recessive disorders 
characterized by the deficiency of enzymes required for the conversion of cholesterol to 
glucocorticoids, mineralocorticoids, and adrenal androgens.1) 21-hydroxylase deficiency 
(21-OHD) CAH (OMIM #201910) accounts for >90% of all cases, with an incidence rate of 
approximately 1 in every 10,000 to 20,000 live births, for all forms of CAH.2) 
It is caused by homozygous, or compound heterozygous, mutations in CYP21A2, on 
chromosome 6p21.3.3) CAH can be broadly dived into early onset classic CAH and late onset 
nonclassical CAH (NC CAH).
The late-onset phenotype (NC CAH) is characterized by normal serum cortisol and 
aldosterone levels and absence of early childhood virilization. Enzyme activity in this form 
ranges from 10% to 40%. Biochemically, variable degrees of hyperandrogenemia are present; 
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however they most often do not cause symptoms until late 
childhood or adolescence, with many patients, particularly 
males, remaining asymptomatic throughout their lives.1) 
Biochemical testing is usually the initial diagnostic step in 
the workup of individuals suspected of having CAH, with 
17 hydroxyprogesterone levels being elevated in all forms 
of 21-OHD. Although the different forms of 21-OHD are 
distinguished on clinical grounds, molecular testing is being 
used more often, especially in cases picked up via newborn 
screening before the clinical phenotype is evident, or where 
biochemical testing is ambiguous.4) Here we present 2 indivi-
duals in a family who underwent long-term treatment for classic 
CAH, before revaluation with molecular testing revealed NC 
CAH not requiring treatment.
Case report
This research related to human use has been complied with 
all the relevant national regulations, institutional policies and 
in accordance with the tenants of the Helsinki declaration, and 
has been approved by the author's or equivalent committee. 
Informed consent was obtained from the parents of the patients.
The proband was a male born to consanguineous parents 
(Fig. 1). He had an acute viral fever at 4 years of age, and was 
found to have mild hyponatremia and hyperkalemia (sodium 
131 mEq/L and potassium 6.1 mEq/L, respectively). Further 
investigation revealed increased 17-hydroxyprogesterone 
(17-OHP) and adrenocorticotropic hormone (ACTH) levels 
(Table 1), and a suboptimal rise in cortisol levels following 
ACTH1-24 stimulation (13.4 μg/dL after 60 minutes). At the 
time of diagnosis proband was of normal growth and stature 
(height=107 cm, z-score=-0.4, 32nd percentile; weight=20.8 kg, 
z-score=+0.8, 80th percentile; body mass index [BMI]=18.2 
kg/m2). Treatment was thus begun for presumed salt wasting 
(SW) CAH using replacement doses of hydrocortisone and 
fludrocortisone. He had normal male genitalia, descended testes, 
and no evidence of precocious adrenarche or puberty. He was 
seen by various providers sporadically over the years, and finally 
was reviewed in our pediatric endocrinology clinic at 17 years 
of age. He was on subphysiologic hydrocortisone replacement 
(7.7 mg/m2/day) as well as fludrocortisone (0.2 mg per day), 
without any symptoms, no history of prostration with illness, 
and normally-timed pubertal changes. He was obese with 
normal stature (height=170 cm, z-score=-0.8, 21st percentile; 
weight=110 kg, z-score=+2.4, 99th percentile; BMI=38.1 kg/m2), 
and had normal testes with Tanner stage V pubic hair. 
After his diagnosis, the 3-year-old sister was screened for 
increased 17-OHP and ACTH levels, which were found to be 
mildly elevated (Table 2). At the time of her diagnosis she was 
also of normal growth and stature (height=94 cm, z-score=-0.05, 
48th percentile; weight=14 kg, z-score=0.03, 51st percentile; 
BMI=15.8 kg/m2). She was also started on physiologic doses 
of  hydrocortisone after ACTH1-24 -stimulation showed 
suboptimal rise in cortisol levels (13.12 μg/dL after 60 minutes). 
She also presented to us in the Pediatric Endocrinology clinic at 
the age of 15 and 11 months, on subphysiologic hydrocortisone 
replacement (8.33 g/m2/day), with no history of virilization, 
precocious puberty or prostration with illness. She was obese 
(height=158 m, z-score=-0.7, 23rd percentile; weight=73.6 
kg, z-score=1.4, 92nd percentile; BMI=29.5 kg/m2), with no 
hirsutism and normal female genitalia (Tanner V breasts and 
pubic hair).
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Fig. 1. The figure shows that the parents of the proband in a consanguineous 
relationship as well as his affected sister and 2 unaffected siblings. CAH, 
congenital adrenal hyperplasia.
Table 1. Results of biochemical testing of brother
Demographic Analytes Results (reference range)
Sampling times (min)
0 30 60
Baseline values (5 yr) 17-OHP (ng/dL) 2,620.0 (<100) - - -
ACTH (AM; pg/mL) 52.9 (<46) - - -
Cortisol (AM; μg/dL) 15.1 (6–25) - - -
ACTH1-24 stimulation (17 yr) Cortisol (μg/dL) - 10.8 12.4 (*) 12.7 (*)
17-OHP (ng/dL) - 8,190.0 10,730.0 (*) 11,390.0 (*)
AM, morning 8:00; 17-OHP, 17 hydroxyprogesterone; ACTH, adrenocorticotropic hormone; ACTH1-24, synthetic ACTH fragment amino 
acids 1-24, cortrosyn; NC CAH, nonclassical congenital adrenal hyperplasia.
*Reference ranges/expected values for stimulated cortisol and 17-OHP: Cortisol: >12 μg/dL denotes a normal response; 17-OHP: 
<1,666 ng/dL–likely unaffected hetrozygote (some overlap with NC CAH), 1000–10,000 ng/dL–NC CAH (some overlap with unaffected 
heterozygotes), >10,000 ng/dL–classic CAH (some minimal overlap with NC CAH).
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We questioned the diagnosis of  SW CAH, since they 
were both asymptomatic on subphysiologic hydrocortisone 
replacement. Work up revealed normal serum electrolytes, 
mildly increased ACTH and stimulated 17-OHP levels, which 
when combined with the lack of any symptoms, led us to 
suspect NC CAH (Tables 1, 2).Thus samples were taken from 
the family and sent for molecular testing.
Participants were tested for the presence of mutation(s) 
within the CYP21A2 gene and large rearrangements between 
CYP21A2 and the CYP21A1P pseudogene. The method used 
was sequencing and multiplex ligation-dependent probe 
amplification.
Molecular testing revealed that the proband had one deleted 
copy of CYP21A2, whereas the other copy harbored a likely 
pathogenic sequence variant (c.748C>T, p.R124C). The p.R124C 
variant has been reported previously in an individual with 
a diagnosis of CAH.5) Previous functional studies indicated 
that this variant has approximately 16% residual activity.5) 
The arginine (R) at this position is highly conserved across 
species and there is a large physicochemical difference between 
arginine (R) and cysteine (C).6) In silico analysis, based on SIFT, 
PolyPhen-2, MutationTaster, and Align GVGD suggests that 
this variant might affect protein function based on the amino 
acid change. SIFT categorized these changes as damaging. 
PolyPhen-2 scored it as probably damaging with HumDiv and 
HumVar scores of 1.000 and 0.997, respectively (scale: 0.000 – 
not damaging – to 1.000 – damaging). MutationTaster classified 
it as "disease causing" with a score of 180 (scale: 0.0 – not disease 
causing – to 215 – disease causing). Finally, AlignGVGD 
gave it a GD score of 70.97, which puts it into the most "likely 
damaging" prediction Class C65 (scale: Class C0 – not damaging 
– to C65 – most likely to be damaging).6,7) Taken together, these 
findings suggested that p.R124C is likely pathogenic. If p.R124C 
is pathogenic, the most likely phenotype due to compound 
heterozygosity for p.R124C and a large deletion would be NC 
CAH. 
The proband’s sister had the same genotype. To our surprise, 
family studies indicated that the father had the same genotype 
as the 2 children, with one copy deleted and the other harboring 
the p.R124C mutation. The mother was heterozygous for 
the large deletion. Therefore, a diagnosis of NC CAH was 
confirmed, and consequently, we discontinued the current 
treatment regimen, with regular follow-up visits. Both siblings 
remain asymptomatic without medication, with mild, expected 
laboratory derangements, proband’s sister had a 17-OHP levels 
(9,072 ng/dL) 1 year after the cessation of medication. Follow-
up testing could not be performed on the proband.
Discussion
Classic CAH and NC CAH differ widely in their phenotypes, 
and thus it is important for clinicians to be able to differentiate 
between the two. 
The diagnosis of CAH is primarily based upon the history, 
physical examination and laboratory values of 17-OHP. The 
Endocrine Society has outlined the diagnostic criteria in its 
consensus statement to aid physicians in the process when 
evaluating patients for 21-OH CAH.2) A useful diagnostic cutoff 
for classic CAH is a stimulated 17-OHP level >10,000 ng/dL, 
1,000–10,000 ng/dL for NC CAH and below 1,666 ng/dL for 
those not affected; this last category will include heterozygotes 
as well as some normal individuals (particularly those who are 
physically stressed, e.g., preterm babies). In addition, an ACTH-
stimulation test and corresponding 17-OHP values are used to 
rule in- or rule out disease.2) However, where the above testing 
inconclusive, such as in this case where the 17-OHP was in the 
range of classic CAH in the brother despite a lack of symptoms, 
molecular testing can be helpful in revealing the underlying 
defect.3)
As mentioned earlier, NC CAH is due to a mutation and/
or deletion of the CYPA21A2 gene that leaves the affected 
individual with a total enzyme activity that is less than 50% 
of a normal person, but larger than about 10%. More severe 
functional impairment is associated with classic CAH.
CYP21A2 and its associated pseudogene(s) (CYP21A1P) 
are located on chromosome 6 within the HLA locus, the 
most highly recombinant portion of the human genome. Not 
surprisingly, this leads to frequent genomic rearrangements 
between CYP21A2 and its highly homologous pseudogene, 
CYP21A1P. These events might create large deletions (involving 
parts or all of CYP21A2 and CYP21A1P, or only CYP21A2), 
Table 2. Results of biochemical testing of sister
Demographic Analytes Results (reference range)
Sampling times (min)
0 30 60
Baseline values (5 yr) 17-OHP (ng/dL) 4,570.0 (<100) - - -
ACTH (AM; pg/mL) 49.0 (<46) - - -
Cortisol (AM; μg/dL) 9.5 (6–25) - - -
ACTH1-24 stimulation (17 yr) Cortisol (μg/dL) - 11.2 13.8 (*) 13.4 (*)
17-OHP (ng/dL) - 4,570.0 9,040.0 (*) 9,520.0 (*)
AM, morning 8:00; 17-OHP, 17 hydroxyprogesterone; ACTH, adrenocorticotropic hormone; ACTH1-24, synthetic ACTH fragment amino 
acids 1-24, cortrosyn; CAH, congenital adrenal hyperplasia.
*Reference ranges/expected values for stimulated cortisol and 17-OHP: Cortisol: >12 μg/dL denotes a normal response; 17-OHP: 
<1,666 ng/dL–likely unaffected hetrozygote (some overlap with NC CAH), 1000–10,000 ng/dL–NC CAH (some overlap with unaffected 
heterozygotes), >10,000 ng/dL–classic CAH (some minimal overlap with NC CAH).
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recombinant hybrids of gene and pseudogene, or microgene 
conversions of CYP21A2, where small portions of CYP21A1P 
get transferred into CYP21A2.4)
Guidelines set out by the Endocrine Society dictate that 
classic CAH be a treated with mineralocorticoids and sodium 
chloride supplements in infancy and Hydrocortisone should 
be given as maintenance therapy. While, symptomatic patients 
with NC CAH should receive the same treatment as their 
CAH counterparts, asymptomatic patients should not receive 
any treatment. Unwarranted diagnosis and treatment not only 
burdens the healthcare infrastructure, but is bothersome for the 
patients even though they are physically healthy. 
To conclude, asymptomatic patients with NC CAH do not 
require aggressive treatment and repetitive diagnostic testing is 
unhelpful.8) Genetic evaluation is important as it identifies the 
specific defect and is helpful when the diagnosis is uncertain. In 
addition, it is also vital to screen the family with genetic testing 
as it will assist in genetic counseling for future offspring and 
allow identification of asymptomatic carriers. 
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